Gold prices steady above $3,400/oz on rate cut bets; PCE data awaited
Investing.com -- InspireMD Inc . (NASDAQ:NSPR) stock climbed 4% in pre-market trading following the commercial launch of its CGuard Prime carotid stent system in the United States.
The company announced that the launch comes after receiving premarket application approval from the Food and Drug Administration. The CGuard Prime system is designed to minimize both early and late embolism risk by trapping potential emboli against arterial walls while maintaining external carotid artery perfusion.
InspireMD’s CGuard Prime features a dual layer design that combines an open-cell frame with what the company describes as the smallest mesh pore size available. The system also incorporates MicroNet™ technology, a bio-stable mesh made from a single 20 μm Polyethylene Terephthalate strand, and SmartFit™ technology that eliminates the need for tapered versions.
"Our U.S. commercial launch marks a pivotal milestone in InspireMD’s expansion history, having already secured double-digit market share across more than 30 countries," said Marvin Slosman, Chief Executive Officer of InspireMD.
Dr. D. Chris Metzger, System Vascular Chief at OhioHealth, noted that the CGuard’s design "makes a real difference in addressing the complexities of carotid artery disease, offering enhanced embolic protection without compromising deliverability."
The company has spent the past year preparing for this launch by building a commercial team of industry veterans to execute its U.S. market entry strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.